In addition, the finding that EG3287 sensitises carcinoma cells to paclitaxel, 5-FU, and cisplatin is of interest since most chemotherapeutic agents have limited efficacy and unwanted side effects, and raises the possibility that NRP1 antagonism may have anticancer potential in combination with conventional chemotherapeutics. The gene discussed is NRP1; the disease is carcinoma.